CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 20 enrolled
Drug / intervention
Vivitydevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05210569
NCT05210569N/ACompleted
CompareCT.gov

Visual Outcomes of the AcrySof® Vivity Intraocular Lens in Patients With High Ocular Axial Length

Dr. James J. Wiens Medical Corporation·observational·Posted Jan 27, 2022·Updated Mar 11, 2025

In Brief

An observational study evaluating Vivity for Cataract. Completed, enrolled 20 participants across 1 site.

Detailed Summary

The objective is to assess the visual outcomes and quality of vision of patients receiving the AcrySof® Vivity Intraocular lens (IOL), when implanted in eyes with high ocular axial length (≥24.5mm), after uneventful cataract surgery.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsCataract
CountriesCanada
CollaboratorsSengi

Timeline

N/ACompletedFinished
20222023202420252026
First PostedJan 27, 2022
Enrollment StartJan 13, 2022
Primary CompletionSep 6, 2023
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 4.4 years ago

Interventions

Vivitydevice

Vivity intraocular lens (IOL)